SlideShare a Scribd company logo

Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (ATTR): Shared Perspectives From Patients and Providers

PeerVoice
PeerVoice

Laura Obici, MD, Lucia Galán Davila, MD, PhD, and David Gregory, discuss ATTR in this CME activity titled "Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (ATTR): Shared Perspectives From Patients and Providers." For the full presentation, please visit us at www.peervoice.com/THW870.

1 of 1
Download to read offline
Organisation Location Website
Amyloidosis Alliance Global
US
Sweden
France
Italy
Germany
UK
Canada
Israel
Ireland
Spain
Spain
Spain
Portugal
Austria
New Zealand
Mexico
Australia
South Korea
The
Netherlands
amyloidosisalliance.org/
amyloidosis-alliance-members/
amyloidosis.org/
famynorrbotten.se/
amylose.asso.fr/
famy.it/
patientenverband-fap.de/
ttramyloidosis.uk/
amyloidosiscanada.org/
amyloidosis.org.il/
amyloidose.nl/
amy.ie/
andradebalear.es/
amilo.es/
enfermedadandradevalverde.com/
paramiloidose.com/
amyloidosis-austria.at/
amyloidosis.co.nz/
ffam.org.mx/
aan.org.au/
amyloidosis.modoo.at/
Amyloidosis Foundation
FaMY Norbotten
The Association Française contre l’Amylose
(AFCA)
The Associazione Italiana Amiloidosi Familiare
Onlus (fAMY)
ATTR Amyloidosis Patient’s Association
(UKATPA)
Canadian Amyloidosis Support Network
Amyloidosis Israel Org
Stichting Amyloïdose Nederland (SAN)
The ATTR Amyloidosis All Ireland
Asociacion Balear Enfermedad Andrade (ABEA)
Asociación Española de Amiloidosis (AMILO)
Asociación Valverdeña de la Enfermedad de
Andrade (ASVEA)
Associaçao Portuguesa de Paramiloidose
Leben mit Amyloidose
New Zealand ATTR Amyloidosis Patients
Association
Fundacion de Familias con Amyloidosis in
Mexico (FFAM)
Australian Amyloidosis Network
Hereditary Amyloidose Hwanwoohoe
FAP-eV
www.peervoice.com/THW40
This Practice Aid is part of an educational activity.
For more information, visit
The information presented here is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment
included here should not be used by clinicians without evaluation of their patients' conditions and possible contraindications, review of any applicable manufacturer's
product information, and comparison with recommendations of other authorities. No endorsement of any products or uses is made or implied by coverage of such in our
materials. No responsibility is taken for errors or omissions in our materials.
ATTR: transthyretin amyloidosis.
ATTR Patient Organisations
Note that this list is not exhaustive; intended only for disease awareness and information.

Recommended

Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call ...
Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call ...Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call ...
Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call ...PeerVoice
 
Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC
Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRCExpert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC
Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRCPeerVoice
 
The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of D...
The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of D...The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of D...
The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of D...PeerVoice
 
TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Signi...
TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Signi...TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Signi...
TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Signi...PeerVoice
 
Building a Better Approach to Obesity Care in Our Clinical Practices
Building a Better Approach to Obesity Care in Our Clinical PracticesBuilding a Better Approach to Obesity Care in Our Clinical Practices
Building a Better Approach to Obesity Care in Our Clinical PracticesPeerVoice
 
Catch Them Before They Fall: A Call to Action for Comprehensive Testing for H...
Catch Them Before They Fall: A Call to Action for Comprehensive Testing for H...Catch Them Before They Fall: A Call to Action for Comprehensive Testing for H...
Catch Them Before They Fall: A Call to Action for Comprehensive Testing for H...PeerVoice
 
Radioligand Therapy and Therapeutic Sequencing in mCRPC
Radioligand Therapy and Therapeutic Sequencing in mCRPCRadioligand Therapy and Therapeutic Sequencing in mCRPC
Radioligand Therapy and Therapeutic Sequencing in mCRPCPeerVoice
 
Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring...
Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring...Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring...
Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring...PeerVoice
 

More Related Content

More from PeerVoice

Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...
Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...
Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...PeerVoice
 
Continuing Our Conversation in HCM: Compelling Questions and Evolving Conside...
Continuing Our Conversation in HCM: Compelling Questions and Evolving Conside...Continuing Our Conversation in HCM: Compelling Questions and Evolving Conside...
Continuing Our Conversation in HCM: Compelling Questions and Evolving Conside...PeerVoice
 
What’s New and What’s Next? Expanding Our Understanding of HCM in 2023
What’s New and What’s Next? Expanding Our Understanding of HCM in 2023What’s New and What’s Next? Expanding Our Understanding of HCM in 2023
What’s New and What’s Next? Expanding Our Understanding of HCM in 2023PeerVoice
 
Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on ...
Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on ...Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on ...
Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on ...PeerVoice
 
Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet N...
Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet N...Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet N...
Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet N...PeerVoice
 
Overcoming Barriers to Better Care in CCA: Keys to Optimising Multidisciplina...
Overcoming Barriers to Better Care in CCA: Keys to Optimising Multidisciplina...Overcoming Barriers to Better Care in CCA: Keys to Optimising Multidisciplina...
Overcoming Barriers to Better Care in CCA: Keys to Optimising Multidisciplina...PeerVoice
 
Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who M...
Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who M...Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who M...
Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who M...PeerVoice
 
Key Updates on the Treatment Paradigm for Systemic Lupus Erythematosus
Key Updates on the Treatment Paradigm for Systemic Lupus ErythematosusKey Updates on the Treatment Paradigm for Systemic Lupus Erythematosus
Key Updates on the Treatment Paradigm for Systemic Lupus ErythematosusPeerVoice
 
Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in R...
Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in R...Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in R...
Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in R...PeerVoice
 
Patients Receiving Immunoglobulin Therapy: Emerging Technology for Patient-In...
Patients Receiving Immunoglobulin Therapy: Emerging Technology for Patient-In...Patients Receiving Immunoglobulin Therapy: Emerging Technology for Patient-In...
Patients Receiving Immunoglobulin Therapy: Emerging Technology for Patient-In...PeerVoice
 
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...PeerVoice
 
Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (...
Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (...Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (...
Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (...PeerVoice
 
The Science and the Art of Modern Prostate Cancer Care: Improving Patient Out...
The Science and the Art of Modern Prostate Cancer Care: Improving Patient Out...The Science and the Art of Modern Prostate Cancer Care: Improving Patient Out...
The Science and the Art of Modern Prostate Cancer Care: Improving Patient Out...PeerVoice
 
Individualising ART as We Travel Through Time: Decisions Along a Life’s Journey
Individualising ART as We Travel Through Time: Decisions Along a Life’s JourneyIndividualising ART as We Travel Through Time: Decisions Along a Life’s Journey
Individualising ART as We Travel Through Time: Decisions Along a Life’s JourneyPeerVoice
 
Incorporating the Investigation of Itch Into the Patient Care Process for PBC...
Incorporating the Investigation of Itch Into the Patient Care Process for PBC...Incorporating the Investigation of Itch Into the Patient Care Process for PBC...
Incorporating the Investigation of Itch Into the Patient Care Process for PBC...PeerVoice
 
Providing State of the Art Care for People With Obesity: Can We Break Free Fr...
Providing State of the Art Care for People With Obesity: Can We Break Free Fr...Providing State of the Art Care for People With Obesity: Can We Break Free Fr...
Providing State of the Art Care for People With Obesity: Can We Break Free Fr...PeerVoice
 
When One Size Doesn’t Fit All: Optimising Molecular Testing and Personalising...
When One Size Doesn’t Fit All: Optimising Molecular Testing and Personalising...When One Size Doesn’t Fit All: Optimising Molecular Testing and Personalising...
When One Size Doesn’t Fit All: Optimising Molecular Testing and Personalising...PeerVoice
 
HIV and Hepatitis B: Managing Coinfections in PLWH
HIV and Hepatitis B: Managing Coinfections in PLWHHIV and Hepatitis B: Managing Coinfections in PLWH
HIV and Hepatitis B: Managing Coinfections in PLWHPeerVoice
 
Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted ...
Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted ...Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted ...
Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted ...PeerVoice
 
Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting
Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and TargetingCatching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting
Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and TargetingPeerVoice
 

More from PeerVoice (20)

Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...
Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...
Approaching Airway Inflammation From Another Angle: The Rationale for Targeti...
 
Continuing Our Conversation in HCM: Compelling Questions and Evolving Conside...
Continuing Our Conversation in HCM: Compelling Questions and Evolving Conside...Continuing Our Conversation in HCM: Compelling Questions and Evolving Conside...
Continuing Our Conversation in HCM: Compelling Questions and Evolving Conside...
 
What’s New and What’s Next? Expanding Our Understanding of HCM in 2023
What’s New and What’s Next? Expanding Our Understanding of HCM in 2023What’s New and What’s Next? Expanding Our Understanding of HCM in 2023
What’s New and What’s Next? Expanding Our Understanding of HCM in 2023
 
Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on ...
Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on ...Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on ...
Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on ...
 
Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet N...
Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet N...Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet N...
Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet N...
 
Overcoming Barriers to Better Care in CCA: Keys to Optimising Multidisciplina...
Overcoming Barriers to Better Care in CCA: Keys to Optimising Multidisciplina...Overcoming Barriers to Better Care in CCA: Keys to Optimising Multidisciplina...
Overcoming Barriers to Better Care in CCA: Keys to Optimising Multidisciplina...
 
Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who M...
Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who M...Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who M...
Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who M...
 
Key Updates on the Treatment Paradigm for Systemic Lupus Erythematosus
Key Updates on the Treatment Paradigm for Systemic Lupus ErythematosusKey Updates on the Treatment Paradigm for Systemic Lupus Erythematosus
Key Updates on the Treatment Paradigm for Systemic Lupus Erythematosus
 
Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in R...
Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in R...Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in R...
Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in R...
 
Patients Receiving Immunoglobulin Therapy: Emerging Technology for Patient-In...
Patients Receiving Immunoglobulin Therapy: Emerging Technology for Patient-In...Patients Receiving Immunoglobulin Therapy: Emerging Technology for Patient-In...
Patients Receiving Immunoglobulin Therapy: Emerging Technology for Patient-In...
 
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...
When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates f...
 
Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (...
Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (...Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (...
Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (...
 
The Science and the Art of Modern Prostate Cancer Care: Improving Patient Out...
The Science and the Art of Modern Prostate Cancer Care: Improving Patient Out...The Science and the Art of Modern Prostate Cancer Care: Improving Patient Out...
The Science and the Art of Modern Prostate Cancer Care: Improving Patient Out...
 
Individualising ART as We Travel Through Time: Decisions Along a Life’s Journey
Individualising ART as We Travel Through Time: Decisions Along a Life’s JourneyIndividualising ART as We Travel Through Time: Decisions Along a Life’s Journey
Individualising ART as We Travel Through Time: Decisions Along a Life’s Journey
 
Incorporating the Investigation of Itch Into the Patient Care Process for PBC...
Incorporating the Investigation of Itch Into the Patient Care Process for PBC...Incorporating the Investigation of Itch Into the Patient Care Process for PBC...
Incorporating the Investigation of Itch Into the Patient Care Process for PBC...
 
Providing State of the Art Care for People With Obesity: Can We Break Free Fr...
Providing State of the Art Care for People With Obesity: Can We Break Free Fr...Providing State of the Art Care for People With Obesity: Can We Break Free Fr...
Providing State of the Art Care for People With Obesity: Can We Break Free Fr...
 
When One Size Doesn’t Fit All: Optimising Molecular Testing and Personalising...
When One Size Doesn’t Fit All: Optimising Molecular Testing and Personalising...When One Size Doesn’t Fit All: Optimising Molecular Testing and Personalising...
When One Size Doesn’t Fit All: Optimising Molecular Testing and Personalising...
 
HIV and Hepatitis B: Managing Coinfections in PLWH
HIV and Hepatitis B: Managing Coinfections in PLWHHIV and Hepatitis B: Managing Coinfections in PLWH
HIV and Hepatitis B: Managing Coinfections in PLWH
 
Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted ...
Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted ...Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted ...
Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted ...
 
Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting
Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and TargetingCatching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting
Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting
 

Recently uploaded

skin diseases shaffer................ppt
skin diseases shaffer................pptskin diseases shaffer................ppt
skin diseases shaffer................pptHimanshu Goyal
 
Seminario Biología Molecular - Susana Cano V.pdf
Seminario Biología Molecular - Susana Cano V.pdfSeminario Biología Molecular - Susana Cano V.pdf
Seminario Biología Molecular - Susana Cano V.pdfsusiedapp
 
Impact of Early Pregnancy---Lecture-2024
Impact of Early Pregnancy---Lecture-2024Impact of Early Pregnancy---Lecture-2024
Impact of Early Pregnancy---Lecture-2024ERWINPEJI2
 
Macquarie Neurosurgery Journal Club 2022 PPT
Macquarie Neurosurgery Journal Club 2022 PPTMacquarie Neurosurgery Journal Club 2022 PPT
Macquarie Neurosurgery Journal Club 2022 PPTMQ_Library
 
Work-role of Radiation Therapists in the Consequences of Adaptive Radiotherap...
Work-role of Radiation Therapists in the Consequences of Adaptive Radiotherap...Work-role of Radiation Therapists in the Consequences of Adaptive Radiotherap...
Work-role of Radiation Therapists in the Consequences of Adaptive Radiotherap...Subrata Roy
 
Anesthesia Implications in cannabis Users.pptx
Anesthesia Implications in cannabis Users.pptxAnesthesia Implications in cannabis Users.pptx
Anesthesia Implications in cannabis Users.pptxhrowshan
 
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptxArtificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptxDr. Dheeraj Kumar
 
Target pain receptors with essential oils
Target pain receptors with essential oilsTarget pain receptors with essential oils
Target pain receptors with essential oilsKevin KF Ng
 
Different Export Prices of Medicinal Drugs.pdf
Different Export Prices of Medicinal Drugs.pdfDifferent Export Prices of Medicinal Drugs.pdf
Different Export Prices of Medicinal Drugs.pdfAsmaa Khalil
 
SUNSCREEN, definition, classification, SPF value, history, mechanism, develop...
SUNSCREEN, definition, classification, SPF value, history, mechanism, develop...SUNSCREEN, definition, classification, SPF value, history, mechanism, develop...
SUNSCREEN, definition, classification, SPF value, history, mechanism, develop...KavyasriPuttamreddy
 
Epidemiological Study Design, Research Design, Clinical Research
Epidemiological Study Design, Research Design, Clinical ResearchEpidemiological Study Design, Research Design, Clinical Research
Epidemiological Study Design, Research Design, Clinical ResearchDr KHALID B.M
 
seminario bio mol- sofia lopez valenciaa
seminario bio mol- sofia lopez valenciaaseminario bio mol- sofia lopez valenciaa
seminario bio mol- sofia lopez valenciaasofialopezvalencia
 
Tolerance Hydra10P Avene trainings blink
Tolerance Hydra10P Avene trainings blinkTolerance Hydra10P Avene trainings blink
Tolerance Hydra10P Avene trainings blinkClinicians
 
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...Abhinav S
 
Seminario biologia molecular-Universidad Pontificia Bolivariana.
Seminario biologia molecular-Universidad Pontificia Bolivariana.Seminario biologia molecular-Universidad Pontificia Bolivariana.
Seminario biologia molecular-Universidad Pontificia Bolivariana.JULIANA BENAVIDES GUERRERO
 
113/02/16-達文西機械手臂手術於耳鼻喉之應用-講師:蘇彥燁主治醫師.pdf
113/02/16-達文西機械手臂手術於耳鼻喉之應用-講師:蘇彥燁主治醫師.pdf113/02/16-達文西機械手臂手術於耳鼻喉之應用-講師:蘇彥燁主治醫師.pdf
113/02/16-達文西機械手臂手術於耳鼻喉之應用-講師:蘇彥燁主治醫師.pdfKs doctor
 
ANTI-HYPERTENSIVE DRUG - RAUWOLFIA ROOT.
ANTI-HYPERTENSIVE DRUG - RAUWOLFIA ROOT.ANTI-HYPERTENSIVE DRUG - RAUWOLFIA ROOT.
ANTI-HYPERTENSIVE DRUG - RAUWOLFIA ROOT.Divya Kanojiya
 
Cell locomotion (Ameboid/ciliary/flagellar movement)
Cell locomotion (Ameboid/ciliary/flagellar movement)Cell locomotion (Ameboid/ciliary/flagellar movement)
Cell locomotion (Ameboid/ciliary/flagellar movement)MedicoseAcademics
 
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.vrchk912
 
Seminario biología molecular Kevin Duque
Seminario biología molecular Kevin DuqueSeminario biología molecular Kevin Duque
Seminario biología molecular Kevin Duquekevinestebanduque
 

Recently uploaded (20)

skin diseases shaffer................ppt
skin diseases shaffer................pptskin diseases shaffer................ppt
skin diseases shaffer................ppt
 
Seminario Biología Molecular - Susana Cano V.pdf
Seminario Biología Molecular - Susana Cano V.pdfSeminario Biología Molecular - Susana Cano V.pdf
Seminario Biología Molecular - Susana Cano V.pdf
 
Impact of Early Pregnancy---Lecture-2024
Impact of Early Pregnancy---Lecture-2024Impact of Early Pregnancy---Lecture-2024
Impact of Early Pregnancy---Lecture-2024
 
Macquarie Neurosurgery Journal Club 2022 PPT
Macquarie Neurosurgery Journal Club 2022 PPTMacquarie Neurosurgery Journal Club 2022 PPT
Macquarie Neurosurgery Journal Club 2022 PPT
 
Work-role of Radiation Therapists in the Consequences of Adaptive Radiotherap...
Work-role of Radiation Therapists in the Consequences of Adaptive Radiotherap...Work-role of Radiation Therapists in the Consequences of Adaptive Radiotherap...
Work-role of Radiation Therapists in the Consequences of Adaptive Radiotherap...
 
Anesthesia Implications in cannabis Users.pptx
Anesthesia Implications in cannabis Users.pptxAnesthesia Implications in cannabis Users.pptx
Anesthesia Implications in cannabis Users.pptx
 
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptxArtificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
Artificial Radionuclide Generators in Medicine Applications in Radiotherapy.pptx
 
Target pain receptors with essential oils
Target pain receptors with essential oilsTarget pain receptors with essential oils
Target pain receptors with essential oils
 
Different Export Prices of Medicinal Drugs.pdf
Different Export Prices of Medicinal Drugs.pdfDifferent Export Prices of Medicinal Drugs.pdf
Different Export Prices of Medicinal Drugs.pdf
 
SUNSCREEN, definition, classification, SPF value, history, mechanism, develop...
SUNSCREEN, definition, classification, SPF value, history, mechanism, develop...SUNSCREEN, definition, classification, SPF value, history, mechanism, develop...
SUNSCREEN, definition, classification, SPF value, history, mechanism, develop...
 
Epidemiological Study Design, Research Design, Clinical Research
Epidemiological Study Design, Research Design, Clinical ResearchEpidemiological Study Design, Research Design, Clinical Research
Epidemiological Study Design, Research Design, Clinical Research
 
seminario bio mol- sofia lopez valenciaa
seminario bio mol- sofia lopez valenciaaseminario bio mol- sofia lopez valenciaa
seminario bio mol- sofia lopez valenciaa
 
Tolerance Hydra10P Avene trainings blink
Tolerance Hydra10P Avene trainings blinkTolerance Hydra10P Avene trainings blink
Tolerance Hydra10P Avene trainings blink
 
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
GERIATRIC PHARMACOLOGY Geriatric pharmacology is a specialized field focusing...
 
Seminario biologia molecular-Universidad Pontificia Bolivariana.
Seminario biologia molecular-Universidad Pontificia Bolivariana.Seminario biologia molecular-Universidad Pontificia Bolivariana.
Seminario biologia molecular-Universidad Pontificia Bolivariana.
 
113/02/16-達文西機械手臂手術於耳鼻喉之應用-講師:蘇彥燁主治醫師.pdf
113/02/16-達文西機械手臂手術於耳鼻喉之應用-講師:蘇彥燁主治醫師.pdf113/02/16-達文西機械手臂手術於耳鼻喉之應用-講師:蘇彥燁主治醫師.pdf
113/02/16-達文西機械手臂手術於耳鼻喉之應用-講師:蘇彥燁主治醫師.pdf
 
ANTI-HYPERTENSIVE DRUG - RAUWOLFIA ROOT.
ANTI-HYPERTENSIVE DRUG - RAUWOLFIA ROOT.ANTI-HYPERTENSIVE DRUG - RAUWOLFIA ROOT.
ANTI-HYPERTENSIVE DRUG - RAUWOLFIA ROOT.
 
Cell locomotion (Ameboid/ciliary/flagellar movement)
Cell locomotion (Ameboid/ciliary/flagellar movement)Cell locomotion (Ameboid/ciliary/flagellar movement)
Cell locomotion (Ameboid/ciliary/flagellar movement)
 
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.
USG,CT AND MR IMAGING OF HEPATIC MASS LESIONS.
 
Seminario biología molecular Kevin Duque
Seminario biología molecular Kevin DuqueSeminario biología molecular Kevin Duque
Seminario biología molecular Kevin Duque
 

Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (ATTR): Shared Perspectives From Patients and Providers

  • 1. Organisation Location Website Amyloidosis Alliance Global US Sweden France Italy Germany UK Canada Israel Ireland Spain Spain Spain Portugal Austria New Zealand Mexico Australia South Korea The Netherlands amyloidosisalliance.org/ amyloidosis-alliance-members/ amyloidosis.org/ famynorrbotten.se/ amylose.asso.fr/ famy.it/ patientenverband-fap.de/ ttramyloidosis.uk/ amyloidosiscanada.org/ amyloidosis.org.il/ amyloidose.nl/ amy.ie/ andradebalear.es/ amilo.es/ enfermedadandradevalverde.com/ paramiloidose.com/ amyloidosis-austria.at/ amyloidosis.co.nz/ ffam.org.mx/ aan.org.au/ amyloidosis.modoo.at/ Amyloidosis Foundation FaMY Norbotten The Association Française contre l’Amylose (AFCA) The Associazione Italiana Amiloidosi Familiare Onlus (fAMY) ATTR Amyloidosis Patient’s Association (UKATPA) Canadian Amyloidosis Support Network Amyloidosis Israel Org Stichting Amyloïdose Nederland (SAN) The ATTR Amyloidosis All Ireland Asociacion Balear Enfermedad Andrade (ABEA) Asociación Española de Amiloidosis (AMILO) Asociación Valverdeña de la Enfermedad de Andrade (ASVEA) Associaçao Portuguesa de Paramiloidose Leben mit Amyloidose New Zealand ATTR Amyloidosis Patients Association Fundacion de Familias con Amyloidosis in Mexico (FFAM) Australian Amyloidosis Network Hereditary Amyloidose Hwanwoohoe FAP-eV www.peervoice.com/THW40 This Practice Aid is part of an educational activity. For more information, visit The information presented here is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment included here should not be used by clinicians without evaluation of their patients' conditions and possible contraindications, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. No endorsement of any products or uses is made or implied by coverage of such in our materials. No responsibility is taken for errors or omissions in our materials. ATTR: transthyretin amyloidosis. ATTR Patient Organisations Note that this list is not exhaustive; intended only for disease awareness and information.